am 251 and naloxone
am 251 has been researched along with naloxone in 18 studies
Research
Studies (18)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bánki, L; Deli, MA; Dvorácskó, S; Horváth, G; Kékesi, G; Keresztes, A; Macedonio, G; Mollica, A; Pieretti, S; Stefanucci, A; Tömböly, C; Tuboly, G; Walter, FR; Zádor, F | 1 |
| Barun, S; Dileköz, E; Ercan, ZS; Sarioglu, Y; Vural, IM | 1 |
| Fazli-Tabaei, S; Kangarlu-Haghighi, K; Khalilzadeh, A; Zarrindast, MR | 1 |
| Chabot, JG; Jhamandas, K; Ma, W; Quirion, R; Trang, T | 1 |
| Ahmadi, S; Nouri, M; Zarrindast, MR | 1 |
| Araya, KA; David Pessoa Mahana, C; González, LG | 1 |
| Blundell, JE; Rodgers, RJ; Tallett, AJ | 1 |
| Hasanein, P | 1 |
| Allen, CP; Lang, ST; Leri, F; Manwell, LA; Parker, LA; Satvat, E | 1 |
| Baamonde, A; Curto-Reyes, V; Hidalgo, A; Llames, S; Menéndez, L | 1 |
| Fang, Q; Han, ZL; He, N; Li, N; Wang, R; Wang, ZL | 1 |
| Hervera, A; Leánez, S; Martín-Campos, JM; Negrete, R; Pol, O | 1 |
| Arulselvan, P; Fakurazi, S; Hairuszah, I; Hidayat, MT; Moklas, MAM; Shamima, AR | 1 |
| Fraga, D; Parada, CA; Rae, GA; Souza, GEP; Zampronio, AR; Zanoni, CIS | 1 |
| Fernandes, PD; Giorno, TBS; Moreira, IGDS; Rezende, CM | 1 |
| Canseco-Alba, A; Rodríguez-Manzo, G | 1 |
| Kvachadze, I; Tsagareli, MG; Tsagareli, N; Tsiklauri, N | 1 |
| Fichna, J; Polepally, PR; Świerczyński, M; Szymaszkiewicz, A; Talar, M; Zielińska, M; Zjawiony, JK | 1 |
Other Studies
18 other study(ies) available for am 251 and naloxone
| Article | Year |
|---|---|
Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Enkephalins; Indoles; Mice; Molecular Structure; Naphthalenes; Oxycodone; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Opioid, mu; Structure-Activity Relationship | 2019 |
Effects of cannabinoid receptor activation on rabbit bisected vas deferens strips.
Topics: Animals; Arachidonic Acids; Benzoxazines; Calcium Channel Blockers; Cannabinoid Receptor Agonists; Dose-Response Relationship, Drug; Endocannabinoids; In Vitro Techniques; Indoles; Male; Morpholines; Muscle Contraction; Muscle, Smooth; Naloxone; Naphthalenes; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rabbits; Receptors, Cannabinoid; Sympathetic Nervous System; Vas Deferens | 2005 |
Influence of intracerebroventricular administration of cannabinergic drugs on morphine state-dependent memory in the step-down passive avoidance test.
Topics: Analgesics, Opioid; Animals; Avoidance Learning; Benzoxazines; Injections, Intraventricular; Male; Memory; Mice; Morphine; Morpholines; Naloxone; Naphthalenes; Narcotic Antagonists; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1 | 2006 |
Spinal modulation of calcitonin gene-related peptide by endocannabinoids in the development of opioid physical dependence.
Topics: Animals; Calcitonin Gene-Related Peptide; Cannabinoid Receptor Modulators; Cannabinoids; Capsaicin; Drug Administration Schedule; Endocannabinoids; Ganglia, Spinal; Hot Temperature; Immunologic Techniques; Male; Morphine; Naloxone; Narcotic Antagonists; Neurons; Nociceptors; Opioid-Related Disorders; Piperidines; Proto-Oncogene Proteins c-fos; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; RNA, Messenger; Spinal Cord; Substance Withdrawal Syndrome | 2006 |
Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzoxazines; Calcium Channel Blockers; Conditioning, Operant; Dose-Response Relationship, Drug; Hippocampus; Male; Microinjections; Morphine; Morpholines; Motor Activity; Naloxone; Naphthalenes; Narcotic Antagonists; Narcotics; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1 | 2007 |
Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
Topics: Animals; Benzoxazines; Brain; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Enzyme Inhibitors; Female; GTP-Binding Protein alpha Subunits, Gi-Go; In Vitro Techniques; Mice; Morpholines; Naloxone; Naphthalenes; Narcotic Antagonists; Ouabain; Pertussis Toxin; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Sodium-Potassium-Exchanging ATPase; Synaptosomes | 2007 |
Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats.
Topics: Animals; Drug Interactions; Eating; Feeding Behavior; Grooming; Male; Motor Activity; Naloxone; Narcotic Antagonists; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Weight Gain | 2009 |
The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis.
Topics: Animals; Arachidonic Acids; Biological Transport; Camphanes; Cannabinoid Receptor Modulators; Cholestasis; Endocannabinoids; Male; Naloxone; Opioid Peptides; Pain; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2009 |
FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats.
Topics: Amidohydrolases; Animals; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Choice Behavior; Conditioning, Psychological; Dietary Sucrose; Extinction, Psychological; Female; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Narcotics; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Reinforcement Schedule; Rimonabant; Species Specificity; Substance Withdrawal Syndrome | 2009 |
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.
Topics: Analgesics; Animals; Bone Neoplasms; Camphanes; Cannabinoids; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Ganglia, Spinal; Humans; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Naloxone; Osteosarcoma; Pain; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB2; Spinal Cord | 2010 |
Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
Topics: Analgesia; Analgesics; Animals; Benzoxazines; Indoles; Male; Mice; Morpholines; Naloxone; Naphthalenes; Oligopeptides; Pain; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2012 |
The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids.
Topics: Analgesics; Analgesics, Opioid; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cyclic GMP; Glyburide; Indoles; KATP Channels; Mice; Mice, Knockout; Naloxone; Nitric Oxide; Nitric Oxide Synthase Type I; Pain; Piperidines; Pyrazoles; Quaternary Ammonium Compounds; Receptors, Cannabinoid; Signal Transduction; Thionucleotides | 2011 |
Antinociceptive action of isolated mitragynine from Mitragyna Speciosa through activation of opioid receptor system.
Topics: Analgesics; Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Male; Mice; Mice, Inbred ICR; Mitragyna; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Opioid; Secologanin Tryptamine Alkaloids | 2012 |
Endocannabinoids, through opioids and prostaglandins, contribute to fever induced by key pyrogenic mediators.
Topics: Animals; Arachidonic Acids; beta-Endorphin; Body Temperature; Corticotropin-Releasing Hormone; Cytokines; Endocannabinoids; Endothelin-1; Fever; Interleukin-1beta; Interleukin-6; Male; Naloxone; Narcotic Antagonists; Piperidines; Polyunsaturated Alkamides; Prostaglandins; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Tumor Necrosis Factor-alpha | 2016 |
New
Topics: Analgesics; Animals; Behavior, Animal; Capsaicin; Coffee; Disease Models, Animal; Female; Formaldehyde; Glutamic Acid; Hot Temperature; Hyperalgesia; Male; Mice; Naloxone; Narcotic Antagonists; Ondansetron; Pain; Pain Measurement; Piperidines; Pyrazoles; Serotonin | 2018 |
Sexual interaction is essential for the transformation of non-copulating rats into sexually active animals by the endocannabinoid anandamide.
Topics: Animals; Arachidonic Acids; Brain; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug; Endocannabinoids; Male; Naloxone; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats, Wistar; Receptor, Cannabinoid, CB1; Sexual Behavior, Animal | 2019 |
Endogenous opioid and cannabinoid systems contribute to antinociception produced by administration of NSAIDs into the insular cortex of rats.
Topics: Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Cortex; Endocannabinoids; Male; Naloxone; Nociception; Opioid Peptides; Piperidines; Pyrazoles; Rats; Rats, Wistar; Somatostatin | 2020 |
Critical interactions between opioid and cannabinoid receptors during tolerance and physical dependence development to opioids in the murine gastrointestinal tract: proof of concept.
Topics: Analgesics, Opioid; Animals; Cannabinoids; Diterpenes, Clerodane; Drug Tolerance; Ileum; Male; Mice; Mice, Inbred BALB C; Morphine; Muscle, Smooth; Naloxone; Piperidines; Pyrazoles; Receptors, Cannabinoid; Substance Withdrawal Syndrome | 2021 |